

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2628747

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ZYMENEX A/S	06/04/2008
RECEIVING PARTY DATA	
Name:	SHIRE PHARMACEUTICALS IRELAND LIMITED
Street Address:	5 RIVERWALK
Internal Address:	CITIWEST BUSINESS CAMPUS
City:	DUBLIN 24
State/Country:	IRELAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13958221
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
Phone:	617-248-5000
Email:	patentdocket@choate.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	CHOATE HALL & STEWART LLP
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2006685-0367
NAME OF SUBMITTER:	KEVIN J. POBURYSKY
Signature:	/Kevin J. Pobursky/
Date:	11/26/2013
Total Attachments: 2 source=executedAssignment_Zymenex_Shire#page1.tif source=executedAssignment_Zymenex_Shire#page2.tif	

OP \$40.00 13958221

ASSIGNMENT

In consideration of the sum of One Dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned

Zymenex A/S
Roskildevej 12C
3400 Hillerød
Denmark

(hereinafter referred to as the "Assignor")

do hereby declare that we have assigned to

Shire Pharmaceuticals Ireland Limited
5 Riverwalk
Citiwest Business Campus
Dublin 24
Ireland

(hereinafter referred to as the "Assignee")

all our rights to

United States Application No. 10/588,082 for the invention entitled

Production and purification of recombinant arylsulfatase A

This assignment covers the entire right, title and interest in and to the aforesaid invention, the Application, and any and all improvements and/or modifications to the aforesaid invention and Application, and in and to any and all patent applications and/or Letters Patent of the United States or any other country related to the invention, the Application, and/or any and all improvements and/or modifications to the aforesaid invention and applications, including but not limited to, provisional applications, conversions to utility applications, continuations, continuations-in-part, continuing prosecution applications (CPAs), requests for continuing examination (RCEs), reissues, reexaminations, extensions, substitutes, renewals and divisions which may be filed or granted therefor and all rights to claim priority in whole or in part on the basis of the application.

The Assignor hereby covenants for us and our legal representatives, and agrees with said Assignee, its successors and assigns, that we have the full right to convey the entire interest herein conveyed and that we have granted no right or license to make, use, sell or offer to sell said invention, Application, any other applications or properties identified herein, to anyone except said Assignee, that prior to the execution of this deed, our right, title and interest in said invention, Application, or any other applications or properties identified herein had not been otherwise encumbered, and that we have not and will not execute any instrument in conflict with this Assignment.


33686US02

The Assignor hereby covenants and agrees, on their own behalf and on behalf of their successors and assigns, to execute any additional assignments and other documents required in connection with the prosecution of the Application or patent applications as well as to perform any additional acts necessary to enable the Assignee or its successors, legal representatives and assigns, to enjoy the full rights of this Assignment, including applying for a patent for the invention in the United States of America or in any other country of the world, and assigning the Application or any other applications of any other country of the world and any patent or patents issuing thereon to the said Assignee or its successors, legal representatives and assigns.


We hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all Letters Patent of the United States resulting from said application or any division or divisions or continuing or reissue applications thereof to the Assignee, its successors or assigns in accordance herewith.

In witness thereof the parties hereto have executed this assignment as of the day and year stated below.


Place and date:
Copenhagen
June 4, 2008

For Zymenex A/S

Jens Fogh, Managing Director

Place and date:
4 June 2008
Copenhagen

For Zymenex A/S

Thomas Tscherning,
Chairman of the board of directors

Place and date:
30 JUNE 2008
BASINGSTOKE

For Shire Pharmaceuticals Ireland Limited

Iain Ward
SENIOR COUNSEL

33686USC2